ABUS — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

10.74

Margin Of Safety %

Put/Call OI Ratio

0.7

EPS Next Q Diff

EPS Last/This Y

-0.06

EPS This/Next Y

Price

4.46

Target Price

5.25

Analyst Recom

Performance Q

-5.31

Upside

-152.5%

Beta

0.74

Ticker: ABUS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	ABUS	4.71	0.72	0.02	39144
2026-03-10	ABUS	4.72	0.71	0.09	39271
2026-03-11	ABUS	4.72	0.71	0.02	39308
2026-03-12	ABUS	4.32	0.71	0.15	39322
2026-03-13	ABUS	4.32	0.71	0.51	39322
2026-03-17	ABUS	4.36	0.70	1.57	39475
2026-03-18	ABUS	4.26	0.67	0.00	38677
2026-03-19	ABUS	4.36	0.67	1.00	38662
2026-03-20	ABUS	4.26	0.69	0.50	42484
2026-03-23	ABUS	4.41	0.86	0.00	17264
2026-03-24	ABUS	4.32	0.79	0.04	18158
2026-03-25	ABUS	4.53	0.77	0.01	18350
2026-03-26	ABUS	4.46	0.74	0.01	18768
2026-03-27	ABUS	4.3	0.75	0.00	18741
2026-03-30	ABUS	4.3	0.72	0.00	19178
2026-03-31	ABUS	4.49	0.73	2.38	19011
2026-04-01	ABUS	4.51	0.71	0.00	18867
2026-04-02	ABUS	4.49	0.70	0.00	18989
2026-04-06	ABUS	4.47	0.70	0.89	19041
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	ABUS	4.72	44.9	-	-0.26
2026-03-10	ABUS	4.71	44.9	-	-0.26
2026-03-11	ABUS	4.72	44.9	-	-0.26
2026-03-12	ABUS	4.32	44.9	-	-0.26
2026-03-13	ABUS	4.26	44.9	-	-0.26
2026-03-17	ABUS	4.36	44.9	-	-0.26
2026-03-18	ABUS	4.26	44.9	-	-0.26
2026-03-19	ABUS	4.36	44.9	-	-0.26
2026-03-20	ABUS	4.24	44.9	-	-0.26
2026-03-23	ABUS	4.41	44.9	-	-0.26
2026-03-24	ABUS	4.32	44.9	-	-0.26
2026-03-25	ABUS	4.53	44.9	-	-0.26
2026-03-26	ABUS	4.46	44.9	-	-0.26
2026-03-27	ABUS	4.30	44.9	-	-0.23
2026-03-30	ABUS	4.30	69.7	-	-0.23
2026-03-31	ABUS	4.49	69.7	-	-0.23
2026-04-01	ABUS	4.51	69.7	-	-0.23
2026-04-02	ABUS	4.49	69.7	-	-0.23
2026-04-06	ABUS	4.46	69.7	-	-0.23
2026-04-07	ABUS	4.46	69.7	-	-0.23
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	ABUS	0.00	1.20	9.98
2026-03-10	ABUS	0.00	1.20	9.98
2026-03-11	ABUS	0.00	1.20	9.82
2026-03-12	ABUS	0.00	1.20	9.82
2026-03-13	ABUS	0.00	1.20	9.82
2026-03-17	ABUS	0.00	1.21	9.82
2026-03-18	ABUS	0.00	1.21	9.82
2026-03-19	ABUS	0.00	1.21	9.82
2026-03-20	ABUS	0.00	1.21	9.82
2026-03-23	ABUS	0.00	1.20	9.82
2026-03-24	ABUS	0.00	1.20	9.82
2026-03-25	ABUS	0.00	1.20	10.92
2026-03-26	ABUS	0.00	1.20	10.74
2026-03-27	ABUS	0.00	1.20	10.74
2026-03-30	ABUS	0.00	1.18	10.74
2026-03-31	ABUS	0.00	1.18	10.74
2026-04-01	ABUS	0.00	1.18	10.74
2026-04-02	ABUS	0.00	1.18	10.74
2026-04-06	ABUS	0.00	1.18	10.74
2026-04-07	ABUS	0.00	1.18	10.74
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

Institutional Transactions

1.18

Beta

0.74

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

31.4

Max Drawdown 5-Year %

-63.4

Target Price

5.25

P/E

Forward P/E

PEG

P/S

61.92

P/B

11.21

P/Free Cash Flow

EPS

-0.18

Average EPS Est. Cur. Y

-0.23

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-237.88

Relative Volume

0.38

Return on Equity vs Sector %

-71.2

Return on Equity vs Industry %

-54.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ ABUS Healthcare

$4.46

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

15/25

Volume

8/15

Valuation

7/20

TP/AR

2/10

Options

0/10

RSI

51.5

Range 1M

41.1%

Sup Dist

1.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

14/30

Estimates

1/20

Inst/Vol

4/15

Options

0/10

EPS Yr

32.4%

EPS NY

52W%

72.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +17.7% upside

Quality

6/30

Valuation

4/30

Growth

9/25

Stability

8/10

LT Trend

0/5

Upside

+17.7%

Quality

Arbutus Biopharma Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 19

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

ABUS

Latest News

—

Caricamento notizie per ABUS…

stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today

news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance

stock history ABUS – Arbutus Biopharma Corporation invest stock market

stock prices ABUS premarket after hours

ticker ABUS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ABUS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y